Milgrom Daniel P, Lad Neha L, Koniaris Leonidas G, Zimmers Teresa A
Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Curr Osteoporos Rep. 2017 Apr;15(2):76-87. doi: 10.1007/s11914-017-0354-3.
In this article, we will discuss the current understanding of bone pain and muscle weakness in cancer patients. We will describe the underlying physiology and mechanisms of cancer-induced bone pain (CIBP) and cancer-induced muscle wasting (CIMW), as well as current methods of diagnosis and treatment. We will discuss future therapies and research directions to help patients with these problems.
There are several pharmacologic therapies that are currently in preclinical and clinical testing that appear to be promising adjuncts to current CIBP and CIMW therapies. Such therapies include resiniferitoxin, which is a targeted inhibitor of noceciptive nerve fibers, and selective androgen receptor modulators, which show promise in increasing lean mass. CIBP and CIMW are significant causes of morbidity in affected patients. Current management is mostly palliative; however, targeted therapies are poised to revolutionize how these problems are treated.
在本文中，我们将探讨目前对癌症患者骨痛和肌肉无力的认识。我们将描述癌症诱导性骨痛（CIBP）和癌症诱导性肌肉消耗（CIMW）的潜在生理学和机制，以及当前的诊断和治疗方法。我们将讨论未来的治疗方法和研究方向，以帮助患有这些问题的患者。
目前有几种正在进行临床前和临床试验的药物疗法，似乎有望成为当前CIBP和CIMW疗法的辅助手段。此类疗法包括瑞香毒素，它是伤害感受性神经纤维的靶向抑制剂，以及选择性雄激素受体调节剂，它们在增加瘦体重方面显示出前景。CIBP和CIMW是受影响患者发病的重要原因。目前的管理大多是姑息性的；然而，靶向治疗有望彻底改变这些问题的治疗方式。
